Plain-English translation of NCT07348055 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new injectable medication called GR1803 to see if it can safely and effectively treat systemic lupus erythematosus (lupus), an autoimmune disease where the body's immune system mistakenly attacks its own tissues. Researchers want to find out how well this medication works and what side effects patients might experience. The study will enroll about 44 people and test four different dose levels of the medication.
Lupus is a chronic autoimmune disease that can be difficult to treat and cause significant damage to the body. This trial exists to see whether this new medication offers patients a better or additional treatment option beyond the current standard therapies.
You likely qualify if…
You likely don't qualify if…
Participants will receive injections of the medication at one of four dose levels during the study. The exact schedule of visits and how long the study lasts are not detailed here, but you would need to attend clinic visits for the injections and for the research team to monitor your health and check for any side effects.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
China
Safety & dosing / Early efficacy
Sponsor
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Enrollment target
~44 participants
Started
February 2026
Primary completion
June 2027
Age range
18 Years – 60 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Nian
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.